Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C17H19N5O2.2C4H4O4 |
| Molecular Weight | 557.5094 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 2 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(=O)\C=C/C(O)=O.OC(=O)\C=C/C(O)=O.NCCNC1=CC=C(NCCN)C2=C1C(=O)C3=C(C=NC=C3)C2=O
InChI
InChIKey=SVAGFBGXEWPNJC-SPIKMXEPSA-N
InChI=1S/C17H19N5O2.2C4H4O4/c18-4-7-21-12-1-2-13(22-8-5-19)15-14(12)16(23)10-3-6-20-9-11(10)17(15)24;2*5-3(6)1-2-4(7)8/h1-3,6,9,21-22H,4-5,7-8,18-19H2;2*1-2H,(H,5,6)(H,7,8)/b;2*2-1-
| Molecular Formula | C4H4O4 |
| Molecular Weight | 116.0722 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 1 |
| Optical Activity | NONE |
| Molecular Formula | C17H19N5O2 |
| Molecular Weight | 325.3651 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Pixantrone is a novel anthracenedione. It is a weak inhibitor of topoisomerase II. Pixantrone directly alkylates DNA forming stable DNA adducts and cross-strand breaks. Pixuvri is approved for the treatment of adult patients with multiply relapsed or refractory aggressive Non-Hodgkin lymphomas. It is used for patients whose cancer does not respond or has returned after they have received other chemotherapy treatments. The most frequent AE were seen in the blood (mainly neutropaenia), gastrointestinal (nausea, abdominal pain, constipation) and respiratory systems (cough, dyspnea). No drug-drug interaction studies have been submitted and no drug interactions have been reported in human subjects
CNS Activity
Originator
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Topoisomerase II DNA cleavage stimulation, DNA binding activity, cytotoxicity, and physico-chemical properties of 2-aza- and 2-aza-oxide-anthracenedione derivatives. | 1995 Jul |
|
| Bbr 2778, an aza-anthracenedione endowed with preclinical anticancer activity and lack of delayed cardiotoxicity. | 2001 Nov-Dec |
|
| Characterization of anthracenediones and their photoaffinity analogs. | 2002 Mar 15 |
|
| Solid-state characterization of a novel chemotherapeutic drug. | 2003 Mar |
|
| Pixantrone (Novuspharma). | 2003 May |
|
| A comparison of the benefits of mitoxantrone and other recent therapeutic approaches in multiple sclerosis. | 2004 Apr |
|
| New immunosuppressants with potential implication in multiple sclerosis. | 2004 Aug 15 |
|
| Pixantrone (BBR2778): a new immunosuppressant in multiple sclerosis with a low cardiotoxicity. | 2004 Aug 15 |
|
| Pixantrone (BBR2778) reduces the severity of experimental allergic encephalomyelitis. | 2004 Jun |
|
| The role of pixantrone in the treatment of non-Hodgkin's lymphoma. | 2005 Aug |
|
| Compared benefit of approved and experimental immunosuppressive therapeutic approaches in multiple sclerosis. | 2007 Jun |
|
| Pixantrone (BBR 2778) has reduced cardiotoxic potential in mice pretreated with doxorubicin: comparative studies against doxorubicin and mitoxantrone. | 2007 Jun |
|
| Pixantrone: a novel aza-anthracenedione in the treatment of non-Hodgkin's lymphomas. | 2007 Oct |
|
| Considerations with newer regimens for indolent non-Hodgkin lymphoma. | 2008 Aug |
|
| Pixantrone (BBR2778) reduces the severity of experimental autoimmune myasthenia gravis in Lewis rats. | 2008 Feb 15 |
|
| Synthesis and antitumor evaluation of bis aza-anthracene-9,10-diones and bis aza-anthrapyrazole-6-ones. | 2008 Feb 28 |
|
| Formaldehyde-activated Pixantrone is a monofunctional DNA alkylator that binds selectively to CpG and CpA doublets. | 2008 Jul |
|
| CE can identify small molecules that selectively target soluble oligomers of amyloid beta protein and display antifibrillogenic activity. | 2009 Apr |
|
| Pixantrone: a promising drug in the treatment of non-Hodgkin lymphomas. | 2009 May |
|
| Pixantrone maleate for non-Hodgkin's lymphoma. | 2009 Nov |
|
| Pixantrone for the treatment of aggressive non-Hodgkin lymphoma. | 2010 Aug |
|
| DNA binding by pixantrone. | 2010 Dec 7 |
|
| Lymphoma researchers in search of molecular targets. | 2010 Jul 21 |
|
| Can anthracycline therapy for pediatric malignancies be less cardiotoxic? | 2010 Nov |
|
| New anthracenedione derivatives with improved biological activity by virtue of stable drug-DNA adduct formation. | 2010 Oct 14 |
|
| Differential targeting of immune-cells by Pixantrone in experimental myasthenia gravis. | 2013 May 15 |
Patents
Sample Use Guides
The recommended dose is 50 mg/m^2 of pixantrone on day 1, 8 and 15 of each 28-day cycle for up to 6 cycles.
Route of Administration:
Intravenous
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Oct 21 20:47:29 UTC 2019
by
admin
on
Mon Oct 21 20:47:29 UTC 2019
|
| Record UNII |
P0R64C4CR9
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
EU-Orphan Drug |
EU/3/09/722
Created by
admin on Mon Oct 21 20:47:29 UTC 2019 , Edited by admin on Mon Oct 21 20:47:29 UTC 2019
|
||
|
EMA ASSESSMENT REPORTS |
PIXUVRI (AUTHORIZED: LYMPHOMA, NON-HODGKIN)
Created by
admin on Mon Oct 21 20:47:29 UTC 2019 , Edited by admin on Mon Oct 21 20:47:29 UTC 2019
|
||
|
NCI_THESAURUS |
C582
Created by
admin on Mon Oct 21 20:47:29 UTC 2019 , Edited by admin on Mon Oct 21 20:47:29 UTC 2019
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
9937618
Created by
admin on Mon Oct 21 20:47:29 UTC 2019 , Edited by admin on Mon Oct 21 20:47:29 UTC 2019
|
PRIMARY | |||
|
C82398
Created by
admin on Mon Oct 21 20:47:29 UTC 2019 , Edited by admin on Mon Oct 21 20:47:29 UTC 2019
|
PRIMARY | |||
|
144675-97-8
Created by
admin on Mon Oct 21 20:47:29 UTC 2019 , Edited by admin on Mon Oct 21 20:47:29 UTC 2019
|
PRIMARY | |||
|
M8898
Created by
admin on Mon Oct 21 20:47:29 UTC 2019 , Edited by admin on Mon Oct 21 20:47:29 UTC 2019
|
PRIMARY | Merck Index | ||
|
SUB31562
Created by
admin on Mon Oct 21 20:47:29 UTC 2019 , Edited by admin on Mon Oct 21 20:47:29 UTC 2019
|
PRIMARY | |||
|
CHEMBL167731
Created by
admin on Mon Oct 21 20:47:29 UTC 2019 , Edited by admin on Mon Oct 21 20:47:29 UTC 2019
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE | |||
|
|
PARENT -> SALT/SOLVATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |